文献速递肿瘤 PET/CT

通过全身[68Ga]Ga-PSMA-11 PET/CT显像评估前列腺癌患者的动态代谢异质性:病理病灶与正常器官中[68Ga]Ga-PSMA-11摄取定量分析

Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-27

本研究对10例前列腺癌患者行全身动态[68Ga]Ga-PSMA-11 PET/CT,用四种房室模型拟合病理病灶与正常器官的时间-放射性曲线,比较动力学参数。病理病灶以2T3k模型描述更优,正常器官以2T4k模型描述更优;k3区分生理性与病理性摄取的AUC为0.844(95%CI 0.773-0.915),优于SUVmean(AUC 0.659)等指标。

要点

  • 10例前列腺癌患者行全身动态[68Ga]Ga-PSMA-11 PET/CT,病理病灶动力学以2T3k模型拟合更优。
  • 正常器官高摄取以2T4k模型描述更优,其高Ki主要由K1升高和k3低决定。
  • k3区分生理性与病理性摄取的AUC为0.844(95%CI 0.773-0.915),敏感度82.9%,特异度74.1%。

核心结论

  • 病理病灶与正常器官虽均高摄取[68Ga]Ga-PSMA-11,但动力学参数存在显著差异。
  • k3值在区分高摄取病理病灶与正常器官方面表现出值得注意的能力。
  • 作者认为k3有望作为区分前列腺癌患者病理性与非特异性[68Ga]Ga-PSMA-11摄取的影像生物标志物。

研究设计与样本

  • 对10例前列腺癌患者行全身动态[68Ga]Ga-PSMA-11 PET/CT扫描。
  • 手动勾画高摄取正常器官及病理病灶的感兴趣体积(VOI),生成时间-放射性曲线(TAC)。
  • 将1T1k、1T2k、2T3k、2T4k四种房室模型拟合至各组织TAC,获得K1、k2、k3、k4及Ki等速率常数。
  • 以Akaike信息准则(AIC)选择描述病灶与正常器官摄取的最佳模型,并用ROC曲线分析确定区分生理性与病理性摄取的截断值。

主要发现

  • 在病理病灶和正常器官中,1T1k与1T2k模型的AIC值均相对高于2T3k与2T4k模型。
  • 病理病灶的动力学行为以2T3k模型描述优于2T4k模型,正常器官以2T4k模型描述更优。
  • 高摄取正常器官与病理病灶之间,K1、k2、k3及Ki等动力学指标存在显著差异。
  • 正常器官的高Ki值主要由K1升高和k3低决定,而非k2;病理病灶的高Ki值仅次于肾脏、与唾液腺和脾脏相似,主要由最高的k3值决定。
  • k3区分生理性与病理性摄取的AUC为0.844(95%CI 0.773-0.915),敏感度82.9%,特异度74.1%。

关键数值与推荐

  • 病理病灶最佳拟合模型为2T3k,正常器官最佳拟合模型为2T4k,依据AIC选择。
  • k3区分生理性与病理性摄取的AUC为0.844(95%CI 0.773-0.915),敏感度82.9%,特异度74.1%。
  • SUVmean的AUC为0.659,SUVmax的AUC为0.637,K1的AUC为0.604,k2的AUC为0.634,Ki的AUC为0.651。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to quantitatively assess [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs in prostate cancer using the total-body [68Ga]Ga-PSMA-11 PET/CT and to characterize the dynamic metabolic heterogeneity of prostate cancer. METHODS: Dynamic total-body [68Ga]Ga-PSMA-11 PET/CT scans were performed on ten prostate cancer patients. Manual delineation of volume-of-interests (VOIs) was performed on multiple normal organs displaying high [68Ga]Ga-PSMA-11 uptake, as well as pathological lesions. Time-to-activity curves (TACs) were generated, and the four compartment models including one-tissue compartmental model (1T1k), reversible one-tissue compartmental model (1T2k), irreversible two-tissue compartment model (2T3k) and reversible two-tissue compartmental model (2T4k) were fitted to each tissue TAC. Various rate constants, including K1 (forward transport rate from plasma to the reversible compartment), k2 (reverse transport rate from the reversible compartment to plasma), k3 (tracer binding on the PSMA-receptor and its internalization), k4 (the externalization rate of the tracer) and Ki (net influx rate), were obtained. The selection of the optimal model for describing the uptake of both lesions and normal organs was determined using the Akaike information criteria (AIC). Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off values for differentiating physiological and pathological [68Ga]Ga-PSMA-11 uptake. RESULTS: Both 1T1k and 1T2k models showed relatively high AIC values compared to the 2T3k and 2T4k models in both pathological lesions and normal organs. The kinetic behavior of pathological lesions was better described by the 2T3k model compared to the 2T4k model, while the normal organs were better described by the 2T4k model. Significant variations in kinetic metrics, such as K1, k2, and k3, and Ki, were observed among normal organs with high [68Ga]Ga-PSMA-11 uptake and pathological lesions. The high Ki value in normal organs was primarily determined by elevated K1 and low k3, rather than k2. Conversely, the high Ki value in pathological lesions, ranking second to the kidney and similar to salivary glands and spleen, was predominantly determined by the highest k3 value. Notably, k3 exhibited the highest performance in distinguishing between physiological and pathological [68Ga]Ga-PSMA-11 uptake, with an area under the curve (AUC) of 0.844 (95% CI, 0.773-0.915), sensitivity of 82.9%, and specificity of 74.1%. The k3 values showed better performance than SUVmean (AUC, 0.659), SUVmax (AUC, 0.637), and other kinetic parameter including K1 (AUC, 0.604), k2 (AUC, 0.634), and Ki (AUC, 0.651). CONCLUSIONS: Significant discrepancies in kinetic metrics were detected between pathological lesions and normal organs, despite their shared high uptake of [68Ga]Ga-PSMA-11. Notably, the k3 value exhibits a noteworthy capability to distinguish between pathological lesions and normal organs with elevated [68Ga]Ga-PSMA-11 uptake. This discovery implies that k3 holds promise as a prospective imaging biomarker for distinguishing between pathologic and non-specific [68Ga]Ga-PSMA-11 uptake in patients with prostate cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen R, Ng YL, Yang X, et al. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs. Eur J Nucl Med Mol Imaging. 2023. PMID: 37889299. doi:10.1007/s00259-023-06475-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。